{Reference Type}: Journal Article
{Title}: NIFTP-adjusted risk estimation of Bethesda thyroid cytology categories should consider the indication for FNA according to TIRADS.
{Author}: Leoncini A;Camponovo C;Gamarra E;Piticchio T;Ruinelli L;Rotondi M;Cantisani V;Treglia G;Trimboli P;
{Journal}: Endocrine
{Volume}: 85
{Issue}: 3
{Year}: 2024 Sep 3
{Factor}: 3.925
{DOI}: 10.1007/s12020-024-03800-9
{Abstract}: <B>BACKGROUND: </B>Non-invasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP) was firstly described in 2016. Since NIFTP is thought a non-malignant tumor, the Bethesda system for thyroid cytology proposes two estimations of risk of malignancy of the diagnostic categories, one considering NIFTP as cancer and another one considering it as a benign neoplasm. The present study aimed to review NIFTPs in a single center, re-assess them across categories of three Thyroid Imaging Reporting and Data Systems (TIRADSs), and define the indication for biopsy according to the category-specific size cut-offs.<BR><B>METHODS: </B>The study period was from 2017 to 2023. The institutional database was searched for histologically proven NIFTPs with preoperative ultrasound images. NIFTPs were re-assessed according to the American College of Radiology (ACR), European (EU), and Korean (K) TIRADSs. The indication for biopsy was defined according to TIRADS category-specific size threshold.<BR><B>RESULTS: </B>Twenty NIFTPs from 19 patients were included. The median size of the NIFTPs was 23 mm. According to ultrasound, 80-85% of NIFTPs were at low-intermediate risk and 5-15% at high risk without significant difference among the tree TIRADSs (p = 0.91). The indication for FNA, according to three TIRADSs, was found in 52-58% of cases with no significant difference among systems (p = 0.96).<BR><B>CONCLUSIONS: </B>NIFTPs have heterogeneous presentation according to TIRADSs with very low indication rate for FNA.